Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Pharyngeal Diseases

ClinicalTrials.gov lists 2,349 trials for Pharyngeal Diseases or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 49.

MeSH D010608 Stomatognathic Diseases C07 C09
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 134 Phase 1/2 Phase 1/2 84 Phase 2 Phase 2 464 Phase 2/3 Phase 2/3 34 Phase 3 Phase 3 234 Phase 4 Phase 4 66 Not applicable Not applicable 815 Observational Observational 516 Phase 1 Phase 1 134 Phase 1/2 Phase 1/2 84 Phase 2 Phase 2 464 Phase 2/3 Phase 2/3 34 Phase 3 Phase 3 234 Phase 4 Phase 4 66 Not applicable Not applicable 815 Observational Observational 516

Trials per phase (log scale)

1 more section with rows

12 of the 2,349 trials are tagged with Pharyngeal Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Pharyngeal Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Pharyngeal Diseases trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 11 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 207

1994: 1 trials (Phase 3 1) 1995: 2 trials (Observational 1, Phase 2 1) 1996: 6 trials (Not applicable 1, Phase 2/3 2, Phase 2 2, Phase 1 1) 1997: 4 trials (Phase 2 2, Phase 1/2 2) 1998: 9 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 4, Phase 1 1) 1999: 12 trials (Observational 1, Not applicable 3, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 3) 2000: 9 trials (Observational 1, Phase 3 3, Phase 2 1, Phase 1/2 2, Phase 1 2) 2001: 16 trials (Observational 4, Not applicable 4, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1 2) 2002: 9 trials (Observational 2, Not applicable 1, Phase 4 2, Phase 2 3, Phase 1 1) 2003: 17 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 3 5, Phase 2 3, Phase 1/2 3, Phase 1 1) 2004: 19 trials (Observational 3, Not applicable 2, Phase 3 6, Phase 2 5, Phase 1 3) 2005: 30 trials (Observational 11, Not applicable 1, Phase 4 2, Phase 3 5, Phase 2/3 1, Phase 2 6, Phase 1 4) 2006: 48 trials (Observational 13, Not applicable 11, Phase 4 1, Phase 3 10, Phase 2/3 1, Phase 2 9, Phase 1/2 1, Phase 1 2) 2007: 51 trials (Observational 13, Not applicable 13, Phase 4 3, Phase 3 3, Phase 2 10, Phase 1/2 3, Phase 1 6) 2008: 39 trials (Observational 10, Not applicable 11, Phase 4 1, Phase 3 1, Phase 2/3 3, Phase 2 9, Phase 1 4) 2009: 45 trials (Observational 13, Not applicable 5, Phase 4 4, Phase 3 10, Phase 2/3 2, Phase 2 6, Phase 1/2 2, Phase 1 3) 2010: 56 trials (Observational 14, Not applicable 19, Phase 4 2, Phase 3 1, Phase 2 16, Phase 1/2 1, Phase 1 3) 2011: 54 trials (Observational 11, Not applicable 15, Phase 4 1, Phase 3 5, Phase 2/3 2, Phase 2 15, Phase 1/2 2, Phase 1 3) 2012: 73 trials (Observational 13, Not applicable 27, Phase 4 3, Phase 3 7, Phase 2 15, Phase 1/2 6, Phase 1 2) 2013: 68 trials (Observational 17, Not applicable 22, Phase 4 4, Phase 3 9, Phase 2/3 2, Phase 2 9, Phase 1/2 2, Phase 1 3) 2014: 70 trials (Observational 11, Not applicable 28, Phase 4 3, Phase 3 9, Phase 2/3 2, Phase 2 14, Phase 1/2 1, Phase 1 2) 2015: 83 trials (Observational 15, Not applicable 32, Phase 4 5, Phase 3 11, Phase 2/3 2, Phase 2 9, Phase 1/2 5, Phase 1 4) 2016: 97 trials (Observational 23, Not applicable 32, Phase 4 4, Phase 3 10, Phase 2 20, Phase 1/2 6, Phase 1 2) 2017: 119 trials (Observational 31, Not applicable 45, Phase 4 3, Phase 3 8, Phase 2/3 1, Phase 2 22, Phase 1/2 4, Phase 1 5) 2018: 141 trials (Observational 23, Not applicable 58, Phase 4 5, Phase 3 14, Phase 2/3 2, Phase 2 26, Phase 1/2 5, Phase 1 8) 2019: 127 trials (Observational 27, Not applicable 49, Phase 4 3, Phase 3 7, Phase 2/3 2, Phase 2 23, Phase 1/2 6, Phase 1 10) 2020: 136 trials (Observational 38, Not applicable 38, Phase 4 3, Phase 3 16, Phase 2 31, Phase 1/2 2, Phase 1 8) 2021: 152 trials (Observational 36, Not applicable 59, Phase 4 1, Phase 3 12, Phase 2/3 2, Phase 2 34, Phase 1/2 3, Phase 1 5) 2022: 180 trials (Observational 40, Not applicable 65, Phase 4 1, Phase 3 12, Phase 2/3 3, Phase 2 41, Phase 1/2 6, Phase 1 12) 2023: 157 trials (Observational 36, Not applicable 64, Phase 4 1, Phase 3 18, Phase 2/3 2, Phase 2 23, Phase 1/2 7, Phase 1 6) 2024: 207 trials (Observational 48, Not applicable 89, Phase 4 5, Phase 3 13, Phase 2/3 3, Phase 2 38, Phase 1/2 3, Phase 1 8) 2025: 157 trials (Observational 29, Not applicable 55, Phase 4 2, Phase 3 21, Phase 2/3 1, Phase 2 34, Phase 1/2 5, Phase 1 10)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 132
2025 157
2024 207
2023 157
2022 180
2021 152
2020 136
2019 127
2018 141
2017 119

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 160 trials starting in 2026 and about 160 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 298 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 1,145 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Pharyngeal Diseases trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 134
Phase 1/2 84
Phase 2 464
Phase 2/3 34
Phase 3 234
Phase 4 66
Not applicable 815
Observational 516
Expanded access 2

How many Pharyngeal Diseases trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 143
Recruiting 370
Enrolling by invitation 20
Active, not recruiting 121
Available 1

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Pharyngeal Diseases trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 49
Fujian Cancer Hospital 18

Which drugs are being tested for Pharyngeal Diseases? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEMBROLIZUMAB 31
TORIPALIMAB 30
"Capecitabine" 29
CETUXIMAB 26
(nab)-paclitaxel 21

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Cisplatin 1 167
Gemcitabine/Gemzar 58
Intensity-Modulated Radiotherapy 40
Radiation Therapy 35
Docetetaxel 34

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Pharyngeal Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Dysphagia 183 26
Mucositis oral 149 10
Dehydration 113 24
Nausea 113 23
Pneumonia 96 23

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Pharyngeal Diseases? (106)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Use of Cervical Fascia to Prevent Pharyngocutaneus Fistula After Total Laryngectomy. The Laryngoscope 2024 Yes
Platelet-rich fibrin: an autologous biomaterial for healing assistance of pharyngeal repair in total laryngectomy. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2021 Yes
Characteristics of pharyngeal paraesthesia symptoms in patients with obstructive sleep apnoea. Sleep & breathing = Schlaf & Atmung 2021 Yes
Pharyngeal-sparing radiation for head and neck carcinoma of unknown primary following TORS assisted work-up. The Laryngoscope 2020 Yes
Risk factors of pharyngocutaneous fistula after total laryngectomy: a systematic review and meta-analysis. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2020 Yes

Showing 5 of 106 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages